12
Sep
2019

10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

The Infodemic Summer
A Glimmer of Hope, and a Premature Celebration
Meet My Friend Who Supported Trump in 2016
Keeping the Faith and Bracing for the Long Slog